SELLAS Life Sciences Group, Inc
Financing
Shares on issue
203.5M
From 57.8M in June 2024
a raise that quarter, at its price
Newest
No limit
S-3ASR of 2026-03-20. An automatic shelf: the form sets no dollar limit. 1 prospectus supplement filed under it since.
$150.0M
TD Securities (USA), agreement of 2026-03-20. No at-the-market sales on file.
Warrants
20K
Priced warrants: 20K at $1.88.
Cash
19.7 quarters
$134.7M cash on hand.
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-11-18 | Public offering | 11,538,462 | $13.00 | $150.0M | 424B5 ↗ |
| 2025-10-24 | Public offering | not available | $1.535 | $31.0M | 424B5 ↗ |
| 2025-01-28 | Registered direct offering incl. 19.69M pre-funded | 27,885,040 | not available | $25.0M | 8-K ↗ |
| 2025-01-28 | Public offering incl. 11.49M pre-funded | 19,685,040 | $1.27 | $25.0M | 424B5 ↗ |
| 2024-07-30 | Public offering incl. 9.48M pre-funded | 15,849,056 | $1.325 | $21.0M | 424B5 ↗ |
| 2024-07-30 | Registered direct offering incl. 15.85M pre-funded | 22,219,126 | not available | $21.0M | 8-K ↗ |